CureVac N.V. (5CV.F)

2.1440 +0.0440 (+2.10%) 收市：09:42PM CEST

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Alexander Zehnder M.B.A., M.D.	CEO, MD & Member of Management Board	978.33k	無	1970
Mr. Pierre Kemula B.Sc.	MD, CFO & Member of Management Board	654.17k	無	1975
Dr. Malte Greune Ph.D.	COO, Member of Management Board & MD	600.74k	無	1965
Dr. Myriam Mendila M.D.	Chief Development Officer, MD & Member of the Management Board	614.49k	無	1966
Dr. Ulrike Gnad-Vogt M.D., Ph.D.	Senior VP & Area Head of Oncology	284.14k	無	1973
Dr. Sarah Fakih	Vice President Corporate Communications & Investor Relations	無	無	無
Mr. Marco Rau L.L.M., Ph.D.	General Counsel	無	無	無
Mr. Thorsten Schuller	Head of Corporate Communications	無	無	無
Slavica Stevanovic-Heck	Head of Human Resources	無	無	無
Dr. Patrick Baumhof	Senior Vice President of Technology	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

公司管治

截至 無 止，CureVac N.V. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。